Home  »  Market Insights   »  Timber Pharmaceuticals LLC (TMBR) Stock Faltering ...

Timber Pharmaceuticals LLC (TMBR) Stock Faltering in Aftermarket, Here’s Why

Timber Pharmaceuticals LLC (TMBR), a clinical-stage biopharmaceutical dermatology company, has plummeted 21.25% in aftermarket trading session and consequently, was trading at $0.63 when last checked. The decrease could be attributed to the announcement of the proposed public offering by the company. On Tuesday, TMBR closed the day at $0.80 after declining 2.03% during the mid-day session.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report


Why TMBR declining?

In the late hours of Tuesday, TMBR announced that it intends to offer and sell in an underwritten public offering, subject to the market and other conditions, shares of its common stock. The company said that each share of the common stock would be sold with a warrant to purchase one share of common stock. The company said that it expects to grant the underwriters with a 30-day option to purchase additional shares of its common stock and/or warrants to purchase shares of its common stock at the public offering price, minus the underwriting discounts and commissions.

Q2 2021 financial results

On 10th August, TMBR reported the financial results for the second quarter of the fiscal year 2021. The quarter ended on 30th June. The company had cash and cash equivalents of $6.12 million on 30th June. The company generated total revenue of $0.38 million during the quarter. The total operating expenses bore by the company during the period were $3.35 million against $14.27 million for the same period of 2020. The company suffered a loss of $2.96 million from operations against $14.27 million for the same period of 2020. The net loss bore by the company during the three months was $2.96 million ($0.08 per share) against $15.24 million ($1.36 per share) for the same period of 2020.

Executive commentary

John Koconis, Chairman and Chief Executive Officer of TMBR, while commenting on the results said that during the second quarter, the company’s core programs continued toward progress. He hoped that looking forward; the company expects to show continuous improvement in its performance parameters.

The future outlook for TMBR

During the last six months, TMBR stock has declined more than 40%. Various factors are perceived to have caused this decline. However, estimates suggest that the company is in a position to remarkably improve its performance in quarters to come.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts




The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell



100% Free. Stop Anytime. No Spam